Scientific paper - Review paper
Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe?
Clinical Obesity, (2021), 1; 12439. https://doi.org/10.1111/cob.12439

Belančić, Andrej; Kresović, Andrea; Troskot Dijan, Marija

Linked objects
COVID-19 | Virtual collection
Cite this document

Belančić, A., Kresović, A. & Troskot Dijan, M. (2021). Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe?. Clinical Obesity, (1), 6. doi: 10.1111/cob.12439

Belančić, Andrej, et al. "Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe?." Clinical Obesity, no. 1, 2021, pp. 6. https://doi.org/10.1111/cob.12439

Belančić, Andrej, Andrea Kresović and Marija Troskot Dijan. "Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe?." Clinical Obesity no. 1 (2021): 6. https://doi.org/10.1111/cob.12439

Belančić, A., Kresović, A. and Troskot Dijan, M. (2021) 'Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe?', Clinical Obesity, (1), pp. 6. doi: 10.1111/cob.12439

Belančić A, Kresović A, Troskot Dijan M. Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe?. Clinical Obesity [Internet]. 2021 January 10 [cited 2024 June 19];(1):6. doi: 10.1111/cob.12439

A. Belančić, A. Kresović and M. Troskot Dijan, "Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe?", Clinical Obesity, no. 1, pp. 6, January 2021. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:347912. [Accessed: 19 June 2024]